HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study

European Journal of Surgical Oncology

Volumn 42, Issue 1, 2016, Pages 140-148

  Nagaraja, V ^a   Shaw, N ^b   Morey, A L ^b   Cox, M R ^a   Eslick, G D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Barrett's oesophagus; HER2; Oesophageal cancer; Oesophageal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SILVER IN SITU HYBRIDIZATION; SMOKING; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; ADULT; AUSTRALIA; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AUSTRALIA; BARRETT ESOPHAGUS; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84953349815     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.08.159     Document Type: Article

References (54)

1. O. Lund, J.M. Hasenkam, M.T. Aagaard, and H.H. Kimose Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia Br J Surg 76 12 1989 1301 1307
2. S.K. Thompson, A.R. Ruszkiewicz, G.G. Jamieson, and et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens Ann Surg Oncol 15 12 2008 3447 3458
3. Y.J. Bang, E. Van Cutsem, A. Feyereislova, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697
4. V. Nagaraja, and G.D. Eslick Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis J Gastrointest Oncol 5 1 2014 67 76
5. R.A. Walker, J.M. Bartlett, M. Dowsett, and et al. HER2 testing in the UK: further update to recommendations J Clin Pathol 61 7 2008 818 824
6. F. Penault-Llorca, M. Bilous, M. Dowsett, and et al. Emerging technologies for assessing HER2 amplification Am J Clin Pathol 132 4 2009 539 548
7. N.L. Spector, and K.L. Blackwell Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 34 2009 5838 5847
8. E.H. Romond, E.A. Perez, J. Bryant, and et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 2005 1673 1684
9. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, and et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 2005 1659 1672
10. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet; 369(9555): 29-36.
11. J. Gu, L. Zheng, Y. Wang, M. Zhu, Q. Wang, and X. Li Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis Tumour Biol 35 6 2014 5315 5321
12. T.S. Bekaii-Saab, J.M. Roda, K.D. Guenterberg, and et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies Mol Cancer Ther 8 11 2009 2983 2991
13. I. Lesnikova, M. Lidang, S. Hamilton-Dutoit, and J. Koch HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens APMIS Acta Pathol Microbiol Immunol Scand 117 10 2009 737 745
14. A. Gowryshankar, V. Nagaraja, and G.D. Eslick HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis J Gastrointest Oncol 5 1 2014 25 35
15. L. Liu, X. Shao, W. Gao, and et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data J Thorac Oncol 5 12 2010 1922 1932
16. A. Chou, N. Waddell, M.J. Cowley, and et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer Genome Med 5 8 2013 78
17. A. Fleischmann, D. Rotzer, R. Seiler, U.E. Studer, and G.N. Thalmann Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours Eur Urol 60 2 2011 350 357
18. A. Gowryshankar, V. Nagaraja, and G.D. Eslick HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis J Gastrointest Oncol 2013
19. T.K. Varghese Jr, W.L. Hofstetter, N.P. Rizk, and et al. The Society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer Ann Thorac Surg 96 1 2013 346 356
20. M. Hofmann, O. Stoss, D. Shi, and et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 7 2008 797 805
21. D.S. Chan, C.P. Twine, and W.G. Lewis Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer J Gastrointest Surg 16 10 2012 1821 1829
22. F.G. Uzunoglu, A.M. Koenig, and J.R. Izbicki The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? Expert Opin Ther Targets 2014 1 6
23. T.P. Brien, R.D. Odze, C.E. Sheehan, B.J. McKenna, and J.S. Ross HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma Hum Pathol 31 1 2000 35 39
24. H.H. Yoon, Q. Shi, W.R. Sukov, and et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas Clin Cancer Res 18 2 2012 546 554
25. U. Reichelt, P. Duesedau, M. Tsourlakis, and et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus Mod Pathol 20 1 2007 120 129
26. R. Langer, S. Rauser, M. Feith, and et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation Mod Pathol 24 7 2011 908 916
27. J.F. Flejou, F. Paraf, F. Muzeau, and et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations J Clin Pathol 47 1 1994 23 26
28. R.H. Hardwick, C.P. Barham, P. Ozua, and et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis Eur J Surg Oncol 23 1 1997 30 35
29. Y. Hu, S. Bandla, T.E. Godfrey, and et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma Mod Pathol 24 7 2011 899 907
30. S.K. Thompson, T.R. Sullivan, R. Davies, and A.R. Ruszkiewicz Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival Ann Surg Oncol 18 7 2011 2010 2017
31. F.G. Duhaylongsod, M.R. Gottfried, J.D. Iglehart, A.L. Vaughn, and W.G. Wolfe The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus Ann Surg 221 6 1995 677 683
32. H. Friess, A. Fukuda, W.H. Tang, and et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3 World J Surg 23 10 1999 1010 1018
33. M.A. Kim, H.J. Lee, H.K. Yang, Y.J. Bang, and W.H. Kim Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma Histopathology 59 5 2011 822 831
34. H.H. Yoon, Q. Shi, W.R. Sukov, and et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma J Clin Oncol 30 32 2012 3932 3938
35. H. Seol, H.J. Lee, Y. Choi, and et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathology - Off J U. S Can Acad Pathol Inc 25 7 2012 938 948
36. P. Birner, B. Jesch, J. Friedrich, and et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression Ann Surg Oncol 18 12 2011 3330 3337
37. N.H. Stoecklein, S.B. Hosch, M. Bezler, and et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer Cancer Cell 13 5 2008 441 453
38. M. Sikkema, P.J. de Jonge, E.W. Steyerberg, and E.J. Kuipers Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis Clin Gastroenterol Hepatol 8 3 2010 235 244 quiz e32
39. A. Mokrowiecka, A. Wierzchniewska-Lawska, B. Smolarz, and et al. Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia - dysplasia - adenocarcinoma sequence Hepatogastroenterology 60 125 2013 1063 1066
40. E. Rossi, S. Grisanti, V. Villanacci, and et al. HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study J Cell Mol Med 13 9b 2009 3826 3833
41. H. Safran, T. Dipetrillo, P. Akerman, and et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma Int J Radiat Oncol Biol Phys 67 2 2007 405 409
42. H.Q. Luo, L. Han, and Y. Jiang Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer Asian Pac J Cancer Prev APJCP 15 13 2014 5343 5348
43. G. Portale, J.A. Hagen, J.H. Peters, and et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients J Am Coll Surg 202 4 2006 588 596
44. A.L. Visbal, M.S. Allen, D.L. Miller, C. Deschamps, V.F. Trastek, and P.C. Pairolero Ivor Lewis esophagogastrectomy for esophageal cancer Ann Thorac Surg 71 6 2001 1803 1808
45. S.H. Bailey, D.A. Bull, D.H. Harpole, and et al. Outcomes after esophagectomy: a ten-year prospective cohort Ann Thorac Surg 75 1 2003 217 222 discussion 22
46. C. Schieman, D.A. Wigle, C. Deschamps, and et al. Patterns of operative mortality following esophagectomy Dis Esophagus 25 7 2012 645 651
47. B.Z. Atkins, A.S. Shah, K.A. Hutcheson, and et al. Reducing hospital morbidity and mortality following esophagectomy Ann Thorac Surg 78 4 2004 1170 1176 discussion -6
48. M.K. Ferguson, T.R. Martin, L.B. Reeder, and J. Olak Mortality after esophagectomy: risk factor analysis World J Surg 21 6 1997 599 603 discussion -4
49. J.B. Hulscher, J.G. Tijssen, H. Obertop, and J.J. van Lanschot Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis Ann Thorac Surg 72 1 2001 306 313
50. S.C. Tomaszek, S.D. Cassivi, M.S. Allen, and et al. An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy Eur J Cardiothorac Surg 37 4 2010 807 813
51. J.B. Hulscher, J.W. van Sandick, A.G. de Boer, and et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus N Engl J Med 347 21 2002 1662 1669
52. J.M. Omloo, S.M. Lagarde, J.B. Hulscher, and et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial Ann Surg 246 6 2007 992 1000
53. M.B. Orringer, B. Marshall, A.C. Chang, J. Lee, A. Pickens, and C.L. Lau Two thousand transhiatal esophagectomies: changing trends, lessons learned Ann Surg 246 3 2007 363 372 discussion 72-4
54. J.M. Müller, H. Erasmi, M. Stelzner, U. Zieren, and H. Pichlmaier Surgical therapy of oesophageal carcinoma Br J Surg 77 8 1990 845 857